Does Rallies show 13F holders for BLTE?

Yes. Rallies tracks hedge fund and 13F ownership data for BLTE, including fund names, share counts, latest tracked quarter, and position changes when available.

Is BLTE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BLTE. It does not provide personalized investment advice.

BLTE (Belite Bio, Inc American Depositary Shares) Stock Analysis - Hedge Fund Holdings

Belite Bio, Inc American Depositary Shares (BLTE) is a publicly traded Healthcare sector company. As of May 20, 2026, BLTE trades at $144.22 with a market cap of $5.71B and a P/E ratio of 0.00. BLTE moved +4.95% today. Year to date, BLTE is -12.29%; over the trailing twelve months it is +114.92%. Its 52-week range spans $43.70 to $200.00. Analyst consensus is strong buy with an average price target of $215.29. Rallies surfaces BLTE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns BLTE stock?

Hedge funds tracked by Rallies that own BLTE include Duquesne Family and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Belite Bio, Inc American Depositary Shares.

BLTE Key Metrics

Key financial metrics for BLTE
Metric	Value
Price	$144.22
Market Cap	$5.71B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$200.00
52-Week Low	$43.70
Volume	150.82K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Top Hedge Funds Holding BLTE

Duquesne Family holds 106.10K shares of BLTE, changed +0.00% as of Mar 31, 2026.
Farallon Capital holds 1.30K shares of BLTE, changed +0.00% as of Mar 31, 2026.

Latest BLTE News

Belite Bio Beats Q1 EPS Estimates, Launches Rolling FDA NDA for Stargardt Treatment — May 20, 2026
Belite Bio climbs as traders refocus on rolling FDA NDA filing for tinlarebant — Apr 30, 2026
Belite Bio slides as FY2026 EPS estimates fall and insider sales trigger profit-taking — Apr 28, 2026
Belite Bio to Present 35.7% Lesion Growth Reduction Data at May 1 Summit — Apr 27, 2026
Belite Bio dips as investors take profits ahead of April 28 conference update — Apr 26, 2026

Recent BLTE Insider Trades

MATA NATHAN L. sold 42 (~$6.54K) on Apr 30, 2026.
MATA NATHAN L. sold 517 (~$80.96K) on Apr 30, 2026.
MATA NATHAN L. sold 340 (~$53.51K) on Apr 30, 2026.

BLTE Analyst Consensus

7 analysts cover BLTE: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $215.29.

Common questions about BLTE

Who owns BLTE stock?: Hedge funds tracked by Rallies that own BLTE include Duquesne Family and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Belite Bio, Inc American Depositary Shares.
Does Rallies show 13F holders for BLTE?: Yes. Rallies tracks hedge fund and 13F ownership data for BLTE, including fund names, share counts, latest tracked quarter, and position changes when available.
Is BLTE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BLTE. It does not provide personalized investment advice.